Aileron Therapeutics, Inc. (ALRN) |
|
0.3002 -0.112 (-27.14%)
|
06-29 18:45 |
|
Open: |
0.38 |
Pre. Close: |
0.412 |
|
High:
|
0.38 |
Low:
|
0.2633 |
|
Volume:
|
3,367,849 |
Market Cap:
|
27(M) |
|
|
|
|
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.38 - 0.38 |
0.38 - 0.38 |
|
Low:
|
0.26 - 0.26 |
0.26 - 0.26 |
|
Close:
|
0.3 - 0.3 |
0.3 - 0.3 |
|
Technical analysis |
as of: 2022-06-29 4:51:22 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.46 One year: 0.56 |
| Support: |
Support1: 0.26 Support2: 0.21 |
| Resistance: |
Resistance1: 0.39 Resistance2: 0.47 |
| Pivot: |
0.39 |
| Moving Average: |
MA(5): 0.38 MA(20): 0.4
MA(100): 0.45 MA(250): 0.69 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 37.9 %D(3): 39.7  |
| RSI: |
RSI(14): 30.4 |
| 52-week: |
High: 1.26 Low: 0.26 |
| Average Vol(K): |
3-Month: 318 (K) 10-Days: 601 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALRN ] has closed below the lower bollinger band by 32.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ALRN ] is to continue within current trading range. Bollinger Bands are 12.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 29 Jun 2022
US stocks mixed at close of trade; Dow Jones Industrial Average up 0.27% By Investing.com - Investing.com
Wed, 29 Jun 2022
Aileron drug fails to beat placebo in reducing chemo toxicities in lung cancer in trial - Seeking Alpha
Wed, 29 Jun 2022
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer - BioSpace
Tue, 28 Jun 2022
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer - GuruFocus.com
Wed, 08 Jun 2022
$ALRN Aileron Therapeutics Files For Mixed Shelf Of Up To $150 Million - CML News
Tue, 07 Jun 2022
Asco 2022 – PMV’s therapeutic window slams shut - Vantage
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
91 (M) |
| Shares Float |
58 (M) |
|
% Held by Insiders
|
9 (%) |
|
% Held by Institutions
|
35.5 (%) |
|
Shares Short
|
154 (K) |
|
Shares Short P.Month
|
145 (K) |
Stock Financials |
|
EPS
|
-0.32 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-1.92 |
|
EPS Est Next Year
|
-1.88 |
|
Book Value (p.s.)
|
0.55 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-51.3 |
|
Return on Equity (ttm)
|
-93.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.19 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.3 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-24 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-0.95 |
|
PEG Ratio
|
-0.5 |
|
Price to Book value
|
0.54 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.15 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
